Skip to main content
SpringerLink
Log in

Clinical Experience with Murine, Human and Genetically Engineered Monoclonal Antibodies

  • Chapter
The Pharmacology of Monoclonal Antibodies

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 113))

Abstract

Monoclonal antibodies (MAbs), by virtue of their unique antigen specificity, have emerged as important biologic reagents with wide ranging clinical utility. Over the last decade, MAbs have moved from the laboratory bench to the forefront of innovative clinical application. Early clinical trials utilized murine antibodies since these could be readily produced by immunizing mice with candidate antigens and generating hybridomas that secrete antigen- specific MAbs (Koehler and Milstein 1975). Extensive clinical experience with murine MAbs has led to the recognition of a number of limitations associated with the use of such xenogeneic proteins. Thus, murine antibodies are immunogenic (Dillman et al. 1984; Khazaeli et al. 1988) and have a short circulating half-life which often makes frequent administration necessary (Meeker et al. 1985; LoBuglio et al. 1988).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aulitzky WE, Schulz TF, Tilg H, Niederwieser D, Larcher K, Ostberg L, Scriba M, Martindale J, Stern AC, Grass P, Mach M, Dierich MP, Huber C (1991) Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J Infect Dis 163:1344–1347

    PubMed  CAS  Google Scholar 

  • Azuma J, Kurimoto T, Tsuji S, Mochizuki N, Fujinaga S, Matsumoto Y, Masuho Y (1991) Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother 10:278–285

    PubMed  CAS  Google Scholar 

  • Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantes L, Templeton MA, Liu J, Oettgen HF, Houghton AN (1990) Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 50:7490–7495

    PubMed  CAS  Google Scholar 

  • Barth W, Wochner R, Waldmann T, Fahey J (1964) Metabolism of human gamma macroglobulins. J Clin Invest 43:1036–1048

    PubMed  CAS  Google Scholar 

  • Begent RHJ, Ledermann JA, Bagshawe KD, Green AJ, Kelly AMB, Lane D, Secher DS, Dewji MR, Baker TS (1990) Chimeric B72.3 antibody for repeated radioimmunotherapy of colorectal carcinoma. Antibody, Immunoconj, Radiopharm 3:86

    Google Scholar 

  • Bone R (1991) Monoclonal antibodies to endotoxin: new allies against sepsis? JAMA 266:1125–1126

    PubMed  CAS  Google Scholar 

  • Brown SL, Miller RA (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651–661

    PubMed  CAS  Google Scholar 

  • Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW, Scannon PJ (1989) Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res 49:6153–6160

    PubMed  CAS  Google Scholar 

  • Caulfield MJ, Barna B, Murthy S (1990) Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-α in patients with malignant melanoma. J Biol Response Mod 9:319–328

    PubMed  CAS  Google Scholar 

  • Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach J-F (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137:830–838

    PubMed  CAS  Google Scholar 

  • Choy EHS, Chikanza IC, Kingsley GH, Panayai GS (1991) Chimeric anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet 338:450

    PubMed  CAS  Google Scholar 

  • Clendeninn NJ, Nethersell ABW, Scott JE, Collier MA (1992) Phase I/II trials of CAMPATH-1H, a humanized anti-lymphocyte monoclonal antibody (MoAb), in non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstr 624). Blood 80:1589

    Google Scholar 

  • Coller BS (1991) Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Harber E, Jennings RB, Katz AM, Morgan HE (eds) The heart and cardiovascular system, 2nd edn. Raven, New York

    Google Scholar 

  • Coller BS, Scudder LE, Beer J, Gold HK, Folts DJ, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H (1991) Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci 614:193–213

    PubMed  CAS  Google Scholar 

  • Cote R, Morrissey D, Houghton A, Thomson T, Daly M, Oettgen H, Old L (1986) Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci USA 83:2959–2963

    PubMed  CAS  Google Scholar 

  • Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, Ritter MA (1986) Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasm. Cancer Res 46:6489–6493

    PubMed  CAS  Google Scholar 

  • Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA (1988) Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 2(8416):894–896

    PubMed  CAS  Google Scholar 

  • DeNardo SJ, DeNardo GL, O’Grady LF, Levy NB, Mills SL, Macey DJ, McGahan JP, Miller CH, Epstein AL (1988) Pilot studies of radioimmunotherapy of B-cell lymphoma and leukemia using 1311 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1:17–34

    Google Scholar 

  • Dillman RO, Beauregard JC, Halpern SE, Clutter M (1986) Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J Biol Response Mod 5:73–83

    PubMed  CAS  Google Scholar 

  • Dillman RO, Shawler DL, Dillman JB, Royston I (1984) Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881–891

    PubMed  CAS  Google Scholar 

  • Dimaggio JJ, Scheinberg DA, Houghton AN (1990) Monoclonal antibody therapy of cancer. In: Pinedo HM, Chabner BA, Longo DL (eds) Cancer chemotherapy and biological response modifiers, annual 11. Elsevier, Amsterdam, pp 177–203

    Google Scholar 

  • Dinarello CA, Mier JW (1987) Current concepts. Lymphokines. N Engl J Med 317:940–945

    PubMed  CAS  Google Scholar 

  • Ellis SG, Navetta GI, Tcheng JT, Weisman HF, Wang AL, Pitt B, Topol EJ (1990) Antiplatlet GPIIb/IIIa (7E3) antibody in elective PTC A: safety and inhibition of platelet function (Abstr 0755). Circulation 82:111–191

    Google Scholar 

  • Emmrich J, Seyfarth M, Fleig WE, Emmrich F (1991) Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 338:570

    PubMed  CAS  Google Scholar 

  • Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, Larson SM, Schlom J (1987) Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MoAb B72.3. Int J Cancer 39:50–59

    PubMed  CAS  Google Scholar 

  • Fauci AS (1987) Immunomodulators in clinical medicine. Ann Intern Med 106: 421–433

    PubMed  CAS  Google Scholar 

  • Fernsten PD, Primus FJ, Greiner JW, Simpson JF, Schlom J (1991) Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612. Cancer Res 51:926–934

    PubMed  CAS  Google Scholar 

  • Fisher CJ, Zimmerman J, Khazaeli MB, Albertson TE, Dellinger RP, Panacek EA, Foulke GE, Dating C, Smith CR, LoBuglio AF (1990) Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Crit Care Med 18:1311–1315

    PubMed  Google Scholar 

  • Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ (1984) Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085–1094

    PubMed  CAS  Google Scholar 

  • Goldberg D, Morel P, Chatenoud L, Boitard C, Menkes CJ, Bertoye P, Revillard J, Bach J (1991) Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 4:617–630

    PubMed  CAS  Google Scholar 

  • Goldenberg DM (1989) Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin Nuclear Med 19:3392–3396

    Google Scholar 

  • Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO (1991) Targeting, dosimetry and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548–564

    PubMed  CAS  Google Scholar 

  • Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE (1989) Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 81:775–781

    PubMed  CAS  Google Scholar 

  • Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, and the XOMA Sepsis Study Group (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1102

    PubMed  CAS  Google Scholar 

  • Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA (1992a) Serotherapy of B-cell neoplasms with anti-B4 blocked ricin: a phase I trial of daily bolus infusion. Blood 79: 576–585

    PubMed  CAS  Google Scholar 

  • Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992b) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863–878

    PubMed  CAS  Google Scholar 

  • Hafler DA, Ritz J, Schlossman SF, Weiner HL (1988) Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis: immunosuppressive effects and human anti-mouse responses. J Immunol 141:131–138

    PubMed  CAS  Google Scholar 

  • Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H (1988) Remission induction in non-Hodgkin’s lymphoma with reshaped human monoclonal antibody CAMPATH 1-H. Lancet 2:1394–1395

    PubMed  CAS  Google Scholar 

  • Hertier AA, Frankel AE (1989) Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7:1932–1942

    Google Scholar 

  • Herzog C, Walker C, Muller W, Rieber P, Reiter C, Riethmuller G, Wassmer P, Stockinger H, Madic O, Pichler WJ (1989) Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T-cells. J Autoimmun 2:267–282

    Google Scholar 

  • Horneff G, Burnmester GR, Emmrich F, Kalden JR (1991) Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34:129–140

    PubMed  CAS  Google Scholar 

  • Huse W, Sastry L, Iverson S, Kang A, Alting-Mees M, Burton D, Benkovic S, Lerner R (1989) Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275–1281

    PubMed  CAS  Google Scholar 

  • Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by intra-lesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83:8694–8698

    PubMed  CAS  Google Scholar 

  • Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H (1992) Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748–752

    PubMed  CAS  Google Scholar 

  • Jain RK (1987a) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3038–3050

    Google Scholar 

  • Jain RK (1987b) Transport of molecules across tumor vasculature. Cancer Metast Rev 6:559–594

    CAS  Google Scholar 

  • Jain RK (1988) Determinant of tumor blood flow: a review. Cancer Res 48:2641–2658

    PubMed  CAS  Google Scholar 

  • Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125c:373

    CAS  Google Scholar 

  • Jordan RE, Knight DM, Wagner C, McAleer MF, McDonough M, Mattis JA, Coller BS, Weisman HF, Ghrayeb J (1992) A dramatic reduction of the immunogenicity of the anti-GPIIb/IIIa monoclonal antibody, 7E3 Fab, by humanization of the murine constant domains (Abstr 1637). Circulation 86:1–411

    Google Scholar 

  • Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF (1988) Phase I trial of multiple large doses of murine monoclonal antibody C017–1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 80:937–942

    PubMed  CAS  Google Scholar 

  • Khazaeli MB, Wheeler R, Rogers K, Teng N, Ziegler E, Haynes A, Saleh MN, Hardin JM, Bolmer S, Cornett J, Berger H, LoBuglio AF (1990) Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans. J Biol Response Mod 9:178–184

    PubMed  CAS  Google Scholar 

  • Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio AF (1991) Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res 51:5461–5466

    PubMed  CAS  Google Scholar 

  • Khazaeli MB, Saleh MN, Liu TP, Kaladas PM, Gilman SC, LoBuglio AF (1992) Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody. J Clin Immunol 12:116–121

    PubMed  CAS  Google Scholar 

  • Kirkwood JM, Ernstoff MS (1984) Interferons in the treatment of human cancer. J Clin Oncol 4:336–351

    Google Scholar 

  • Knapp RC, Lau CC (1990) Monoclonal antibodies and radioimmunoconjugates: keeping feasibility at center stage. J Clin Oncol 8:1938–1940

    PubMed  CAS  Google Scholar 

  • Koehler G, Milstein C (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495–496

    CAS  Google Scholar 

  • Köhler H, Kieber-Emmons T, Srinivhsan S, Kaveri S, Morris WJW, Muller S, Kang C-Y, Raychanduri S (1989) Short analytical review: revised immune network concepts. Clin Immunol Immunopathol 52:104

    PubMed  Google Scholar 

  • Koprowski H, Herlyn D, Lübeck M, DeFreitas E, Sears H (1984) Human antiidiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 81:216–219

    PubMed  CAS  Google Scholar 

  • Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos A A (1992) Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 52:904–911

    PubMed  CAS  Google Scholar 

  • Kronenberg M (1991) Self tolerance and autoimmunity. Cell 65:537

    PubMed  CAS  Google Scholar 

  • Kumar V, Kono DH, Urban JL, Hood L (1989) The T-cell receptor repertoire and autoimmune diseases. Annu Rev Immunol 7:657

    PubMed  CAS  Google Scholar 

  • Kuzel TM, Winter JN, Rosen ST, Zimmer AM (1990) Monoclonal antibody therapy of lymphoproliferative disorders. Oncology 4:77–93

    PubMed  CAS  Google Scholar 

  • Lenhard RE Jr, Order SE, Spunberg JJ, Asbell SO, Leibel SA (1985) Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin’s disease. J Clin Oncol 3:1296–1300

    PubMed  Google Scholar 

  • Lind P, Lechner P, Hausmann B, Smola MG, Koeltringer P, Steindorfer P, Cesnik H, Passl R, Eber O (1991) Development of human antimouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibody Immunoconj Radiopharm 4:811–818

    Google Scholar 

  • LoBuglio AF, Saleh MN (1992) Monoclonal antibody therapy of cancer. Crit Rev Oncol Hematol 13:271–282

    PubMed  CAS  Google Scholar 

  • LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH (1988) Phase I trial of multiple large doses of murine monoclonal antibody C017–1A. I. Clinical aspects. J Natl Cancer Inst 80:932–936

    PubMed  CAS  Google Scholar 

  • LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86:4220–4224

    PubMed  CAS  Google Scholar 

  • LoBuglio AF, Liu T, Khazaeli MB (1992) Human and chimeric mouse/human monoclonal antibodies. In: Kung AHC, Baughman RA, Larrick JW (eds) Therapeutic proteins: pharmacokinetics and pharmacodynamics. Freeman, New York, pp 45–61

    Google Scholar 

  • Mathieson DW, Cobbold SP, Hale G, Clark MR, Oliverira DBG, Lockwood CM, Waldmann H (1990) Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 323:250–255

    PubMed  CAS  Google Scholar 

  • Meeker T, Lowder J, Maloney D, Miller R, Thielemans K, Warnke R, Levy R (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349–1363

    PubMed  CAS  Google Scholar 

  • Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB (1991) Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, κ 17–1A monoclonal antibody. J Nucl Med 32:1162–1168

    PubMed  CAS  Google Scholar 

  • Meredith RF, Khazaeli MB, Liu TP, Plott G, Wheeler RH, Russell C, Colcher D, Schlom J, Shochat D, LoBuglio AF (1992a) Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33:1648–1653

    PubMed  CAS  Google Scholar 

  • Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu TP, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J, Shochat D, Wheeler RH, LoBuglio AF (1992b) Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 33:23–29

    PubMed  CAS  Google Scholar 

  • Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of a B cell lymphoma with monoclonal anti-idiotypic antibody. N Engl J Med 306:517–522

    PubMed  CAS  Google Scholar 

  • Miller RA, Hart S, Samoszuk M, Coulter C, Brown S, Czerwinski D, Kelkenberg J, Royston I, Levy R (1989) Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med 321:851–857

    PubMed  CAS  Google Scholar 

  • Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, Everson MP, Daddona P, Ghrayeb J, Kilgarrif C, Sanders ME, Koopman WJ (1993a) Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 34(3):307–318

    Google Scholar 

  • Moreland LW, Heck LW, Sullivan W, Pratt PW, Koopman WJ (1993b) New approaches to the therapy of autoimmune diseases: Rheumatoid arthritis as a paradigm. Am J Med Sci 305:40–51

    PubMed  CAS  Google Scholar 

  • Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229: 1202–1207

    PubMed  CAS  Google Scholar 

  • Oldham RK (1991) Custom-tailored drug immunoconjugates in cancer therapy. Mol Biother 3:148–162

    PubMed  CAS  Google Scholar 

  • Order S, Sleeper A, Stillwagon G, Klein T, Leichner P (1989) Current status of radioimmunoglobulins in the treatment of human malignancy. Oncology 3: 115–120

    Google Scholar 

  • Ortho Multicenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337–342

    Google Scholar 

  • Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED, Bernstein ID (1989) Treatment of refractory non-Hodgkin’s lymphomas with radiolabeled MB-1 (anti CD-37) antibody. J Clin Oncol 7: 1027–1038

    PubMed  CAS  Google Scholar 

  • Reisfeld R, Yang H, Muller B, Wargalla U, Schrappe M, Wrasidlo W (1989) Promises, problems, and prospects of monoclonal antibody-drug conjugates for cancer therapy. Antibody Immunoconj Radiopharm 2:217–224

    CAS  Google Scholar 

  • Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K (1991) Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 34:525–536

    PubMed  CAS  Google Scholar 

  • Reynolds JC, Del Vecchio S, Sakahara H (1989) Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol 16:121–125

    CAS  Google Scholar 

  • Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323–327

    PubMed  CAS  Google Scholar 

  • Robinson BE, Quesenbery PJ (1990) Hematopoietic growth factors. Overview and clinical application (Review). Ann J Med Sci 163:237–311

    Google Scholar 

  • Roitt I, Brostoff J, Make D (eds) (1991) Immunology, 3rd edn. Gower, London

    Google Scholar 

  • Rustagi PK, Meluch AA, Khazaeli MB, Liu T, Morris DL, Soule HR, LoBuglio AF (1992) Clinical study of a monoclonal antibody (Fab) to factor VII, a novel anticoagulant (Abstr 655). Blood 80:166a

    Google Scholar 

  • Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY, Khazaeli MB (1990) A phase II trial of murine monoclonal antibody 17–1A and interferon-γ: clinical and immunologic data. Cancer Immunol Immunother 32:185–190

    PubMed  CAS  Google Scholar 

  • Saleh M, Khazaeli M, Wheeler R, Allen L, Liu T, Schlom J, LoBuglio A (1992a) A phase I trial of the murine monoclonal antibody (MoAb) D612 in patient with metastatic colorectal cancer (Abstr 821). Cancer Res 53:4555–4562

    Google Scholar 

  • Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF (1992b) A phase I trial of the chimeric anti-GD2 monoclonal antibody chl4.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3:19–24

    PubMed  CAS  Google Scholar 

  • Saleh MN, Khazaeli MB, Wheeler RH, Liu TP, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF (1992c) A phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52:4342–4347

    PubMed  CAS  Google Scholar 

  • Saravolatz LD, Markowitz N, Collins MS, Bogdanoff D (1991) Safety, pharmacokinetics, and functional activity of human anti-pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. J Infect Dis 164:803–806

    PubMed  CAS  Google Scholar 

  • Schlom J (1990) Monoclonal antibodies: they’re more and less than you think. In: Broder S (ed) Molecular foundations of oncology. Williams and Wilkins, Baltimore, pp 95–134

    Google Scholar 

  • Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr (1985) Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879–885

    PubMed  CAS  Google Scholar 

  • Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Häyry P, Koprowski H (1982) Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1:762–765

    PubMed  CAS  Google Scholar 

  • Sears HF, Herlyn D, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45:5910–5913

    PubMed  CAS  Google Scholar 

  • Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135: 1530–1535

    PubMed  CAS  Google Scholar 

  • Simoons ML, vd Brand M, Hoorntje JCA, de Feyter P, Zijilstra F, Heyndricks G, vd Wicken R, De Bono D, Rutsch W, Weisman HF, Schaible TF, deBoer MJ (1993) Chimeric 7E3 antiplatelet antibody Fab for treatment of refractory unstable angina: a placebo-controlled pilot study (Abstr 768–1). J Am Coll Cardiol 21:269A

    Google Scholar 

  • Sinha AA, Lopez MT, McDevitt HO (1990) Autoimmune diseases: the failure of self tolerance. Science 248:1380–1387

    PubMed  CAS  Google Scholar 

  • Smith CR, Straube RC, Ziegler EJ (1992) A human monoclonal antibody for the treatment of gram-negative sepsis. Infect Dis Clin North Am 6:253–266

    PubMed  CAS  Google Scholar 

  • Steis RG, Carrasquillo JA, McCabe R, Bookman M, Reynolds J, Larson S, Smith J, Clark J, Dailey V, Del Vecchio S (1990) Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476–490

    PubMed  CAS  Google Scholar 

  • Stewart JSW, Hird V, Snook D, Phokia B, Sivolapenko A, Hooker G, Papadimitriou JT, Rowlinson G, Sullivan M, Lambert HE, Coulter C, Mason WP, Soutter WP, Epenetos AA (1990) Intraperitoneal yttrium-90 labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8:1941–1950

    PubMed  CAS  Google Scholar 

  • Sweeney J, Holme S, Heaton A, Weisman H, Whitley P, Barackman K, O’Donnell D, Herre J (1993) Infusion of a chimeric monoclonal Fab fragment (c7E3) against platelet glycoprotein IIB-IIIA potently inhibits platelet aggregation but does not affect in vivo platelet survival (Abstr 911–41). J Am Coll Cardiol 21:253A

    Google Scholar 

  • Swischer EM, Shawler DL, Collins HA, Bustria A, Hart S, Bloomfield C, Miller RA, Royston I (1991) Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 77:1977–1982

    Google Scholar 

  • Teng N, Kaplan H, Hebert J, Moore C, Douglas H, Wunderlich A, Braude A (1985) Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790–1794

    PubMed  CAS  Google Scholar 

  • Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6:1636–1648

    PubMed  CAS  Google Scholar 

  • Van der Lubbe P, Miltenburg AM, Breedveid FC (1991) Anti-CD4 monoclonal antibody for relapsing polychondritis. Lancet 337:1349

    PubMed  Google Scholar 

  • Vitetta ES, Fulton R, May R, Till M, Uhr J (1987) Redesigning nature’s poisons to create anti-tumor reagents. Science 238:1098–1104

    PubMed  CAS  Google Scholar 

  • Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052–4058

    PubMed  CAS  Google Scholar 

  • Waldmann T, Schwab P (1965) IgG (7 S gamma globulin) metabolism in hypogammaglobulinemia: studies in patients with defective gamma globulin synthesis, gastrointestinal protein loss, or both. J Clin Invest 44:1523–1533

    PubMed  CAS  Google Scholar 

  • Weiner LM, O’Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES (1989) Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F6-recombinant ricin A chain immunoconjugate. Cancer Res 49: 4062–4067

    PubMed  CAS  Google Scholar 

  • Wendling D, Wijdenes J, Rachadot E, Morel-Fourrior B (1991) Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 18:325–327

    PubMed  CAS  Google Scholar 

  • Wolff SM (1991) The treatment of gram-negative bacteremia and shock (Editorial). N Engl J Med 324:486–487

    Google Scholar 

  • Yu A, Reisfeld R, Gillies S (1991) Immune response to monoclonal anti-GD2 antibody therapy. Proc Am Assoc Cancer Res 32:263

    CAS  Google Scholar 

  • Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, and the HA-1A Sepsis Study Group (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. N. Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. M. Conry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. F. LoBuglio
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biopharmaceuticals Smith Kline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA, 19406-0939, USA

    Martin Rosenberg Ph.D. (Vice President and Director) (Vice President and Director)

  2. Department of Molecular Genetics, Smith Kline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA, 19406-0939, USA

    Gordon P. Moore Ph.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Saleh, M.N., Conry, R.M., LoBuglio, A.F. (1994). Clinical Experience with Murine, Human and Genetically Engineered Monoclonal Antibodies. In: Rosenberg, M., Moore, G.P. (eds) The Pharmacology of Monoclonal Antibodies. Handbook of Experimental Pharmacology, vol 113. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78432-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78432-3_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78434-7

  • Online ISBN: 978-3-642-78432-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation